These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 28628678)
1. Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face. Jim On SC; Hashim PW; Nia JK; Lebwohl MG J Drugs Dermatol; 2017 May; 16(5):432-436. PubMed ID: 28628678 [TBL] [Abstract][Full Text] [Related]
2. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice. Bettencourt MS J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570 [TBL] [Abstract][Full Text] [Related]
3. A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis. Sinnya S; Tan JM; Prow TW; Primiero C; McEniery E; Selmer J; Østerdal ML; Soyer HP Br J Dermatol; 2016 Feb; 174(2):305-11. PubMed ID: 26499175 [TBL] [Abstract][Full Text] [Related]
4. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis. Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445 [TBL] [Abstract][Full Text] [Related]
5. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT. Berman B; Nestor MS; Newburger J; Park H; Swenson N J Drugs Dermatol; 2014 Nov; 13(11):1353-6. PubMed ID: 25607702 [TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis. Berman B Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Goncalves J; Larsson T; Skov T; Swanson N J Drugs Dermatol; 2014 Feb; 13(2):154-60. PubMed ID: 24509965 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Larsson T; Swanson N J Drugs Dermatol; 2014 Jun; 13(6):741-7. PubMed ID: 24918567 [TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119 [TBL] [Abstract][Full Text] [Related]
10. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial. Erlendsson AM; Karmisholt KE; Haak CS; Stender IM; Haedersdal M J Am Acad Dermatol; 2016 Apr; 74(4):709-15. PubMed ID: 26810403 [TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest. Hanke CW; Berman B; Swanson N; Pariser DM; Weiss JS; Bukhalo M; Skov T; Villumsen J; Siegel D J Drugs Dermatol; 2017 May; 16(5):438-444. PubMed ID: 28628679 [TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365 [TBL] [Abstract][Full Text] [Related]
13. Ingenol mebutate gel for actinic keratosis. Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254 [TBL] [Abstract][Full Text] [Related]
14. A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body. Pellacani G; Peris K; Guillen C; Clonier F; Larsson T; Venkata R; Puig S J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2192-8. PubMed ID: 26300464 [TBL] [Abstract][Full Text] [Related]
15. Regression Analysis of Local Skin Reactions to Predict Clearance of Actinic Keratosis on the Face in Patients Treated With Ingenol Mebutate Gel: Experience from Randomized Controlled Trials. Jim On S; Knudsen KM; Skov T; Lebwohl M J Drugs Dermatol; 2017 Feb; 16(2):112-114. PubMed ID: 28300852 [TBL] [Abstract][Full Text] [Related]
16. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas. Bucko AD; Jarratt M; Stough DB; Kyhl L; Villumsen J; Hall A J Dermatolog Treat; 2018 Feb; 29(1):74-79. PubMed ID: 28524709 [TBL] [Abstract][Full Text] [Related]
18. A multicentre, open, investigator-initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0·015% on the face and scalp, and 0·05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT). Kim YC; Yang JY; Yoon JS; Jo SJ; Ahn HH; Song KH; Lee DY; Chung KY; Won YH; Kim IH Br J Dermatol; 2018 Oct; 179(4):836-843. PubMed ID: 29355904 [TBL] [Abstract][Full Text] [Related]
19. Clinical and Histologic Evaluation of Ingenol Mebutate 0.015% Gel for the Cosmetic Improvement of Photoaged Skin. Handler MZ; Bloom BS; Goldberg DJ Dermatol Surg; 2018 Jan; 44(1):61-67. PubMed ID: 28858927 [TBL] [Abstract][Full Text] [Related]
20. Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp. Stockfleth E; Harwood CA; Serra-Guillén C; Larsson T; Østerdal ML; Skov T Br J Dermatol; 2018 Feb; 178(2):433-442. PubMed ID: 29030864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]